Evidence map›Paper›PMID 39734783›Full record

ArticleChina CDC weekly2024

Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020.

Linying Gao, Xufeng Cui, Xinyuan Mo, Zhaoyue Men, Xiuyang Xu, Tian Yao, Jianmin Wang, Hongting Liu, Hongping Guo, Guowei Chai and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Linying GaoSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Xufeng CuiSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Xinyuan MoSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Zhaoyue MenSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Xiuyang XuSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Tian YaoSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Jianmin WangDepartment of Nephrology, Linfen Central Hospital, Linfen City, Shanxi Province, China.
Hongting LiuDepartment of Nephrology, Yuncheng Central Hospital, Yuncheng City, Shanxi Province, China.
Hongping GuoDepartment of Nephrology, Linfen People's Hospital, Linfen City, Shanxi Province, China.
Guowei ChaiDepartment of Nephrology, Houma People's Hospital, Houma City, Shanxi Province, China.
Liming LiuDepartment of Nephrology, Linfen Central Hospital, Linfen City, Shanxi Province, China.
Fuzhen WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiaofeng LiangInstitute of Vaccine Industry, Jinan University, Guangzhou City, Guangdong Province, China.
Suping WangSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Yongliang FengSchool of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs). What is added by this report?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL. What are the implications for public health practice?: The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.

Indexed as

CKD patientsHepB vaccinehigh-doseImmunogenicityshort-course

Identifiers

PMID39734783
PMCPMC11673178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.